Free Trial

Fujifilm's Avigan Meets Primary Endpoint In Covid P3 Trial

MNI

BBG runs comments from Fujifilm, which says its flu drug Avigan met its primary endpoint in a phase 3 trial in Japan for Covid-19 patients. Fujifilm will now seek regulatory approval for the drug as soon as in October.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.